TrialAmerican journal of nephrology2024

Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers.

Joseph Stavas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.